“Peptide” is not
a safety status.
The same molecule name can appear in an approved label, a compounded preparation, a clinical trial, or a research catalog. Those routes do not share one evidence standard, supply chain, or risk profile.
If someone collapses, has a seizure, has trouble breathing, or cannot be awakened, call 911 immediately. For a possible poisoning or unexpected exposure, contact Poison Control online or at 1-800-222-1222. Outside the US, use the local emergency and poison service.
Open Poison ControlFour routes. Never one price table.
Start here before interpreting a study, seller document, review, or price. The category determines which evidence and verification path can answer the question.
FDA-approved prescription drug
Approval belongs to an exact drug product, formulation, indication, label, and manufacturer - not to a peptide name in the abstract.
- Verify
- Verify the exact prescribed product and strength, the prescriber, and a state-licensed dispensing pharmacy. Compare the label and regulated supply route, not a similarly named vial.
- Boundary
- Approval for one product does not transfer to a compounded preparation, an online research material, another route, or an investigational analogue.
Compounded drug
A compounded drug may meet a patient-specific need, but FDA does not approve compounded drugs or verify their safety, effectiveness, or quality before marketing.
- Verify
- Verify the prescriber, the named pharmacy or outsourcing facility, state records, the patient-specific prescription, the exact formulation and concentration, and the current legal conditions.
- Boundary
- Compounded is not a synonym for generic, FDA approved, clinically equivalent, or identical to a brand-name product.
Investigational medicine
A clinical-trial candidate is studied under a protocol with eligibility criteria, oversight, consent, and defined outcomes. A trial listing or sponsor result is not approval.
- Verify
- Verify the sponsor, NCT identifier, phase, recruitment status, official study sites, intervention, primary outcomes, and record history. Trial access runs through the study, not an online vial listing.
- Boundary
- Promising group-level results do not establish an approved dose, commercial product, individual benefit, or safe unsupervised access.
Research-use-only material
A laboratory research listing is not a prescription, medicine, compounded preparation, supplement, or treatment pathway. The listing belongs outside human and veterinary use.
- Verify
- For legitimate institutional research, verify the exact chemical identity, nominal amount, intended non-clinical work, supplier documentation, handling requirements, and applicable institutional rules.
- Boundary
- A research-use label, seller disclaimer, COA, purity percentage, or product name does not establish approval, clinical safety, sterility, lawful personal use, or vial identity.
Find the missing evidence before it finds you.
This is a reading framework, not a treatment checklist. It identifies where a claim outruns the source attached to it.
What exact product category is this?
Name the route before reading a price, rating, study percentage, or seller claim. Category errors invalidate the rest of the comparison.
Does the evidence match this exact product and lot?
A molecule name, chromatogram, laboratory logo, or report URL is not proof that the material in hand came from the represented sample.
Which attributes were actually examined?
Purity, identity, quantity, sterility, endotoxin, contaminants, and stability are different questions. One result cannot silently answer the others.
Are concentration, amount, and units unambiguous?
FDA has reported compounded-semaglutide errors involving varying concentrations and confusion among milliliters, milligrams, and units. This page does not provide dosing instructions.
Did the exact product stay within labeled conditions?
Storage requirements belong to the exact regulated label or study protocol. FDA has received complaints about compounded injectable GLP-1 products arriving warm.
Is this an emergency, poison exposure, or reportable product problem?
Emergency services, Poison Control, a treating professional, and FDA MedWatch serve different purposes. A comparison website serves none of them.
Why a live safety page needs dates.
FDA’s current unapproved GLP-1 page says unapproved versions do not undergo FDA review for safety, effectiveness, and quality before marketing. It also identifies dosing-error, fraudulent-label, salt-form, storage, and adverse-event concerns for compounded semaglutide and tirzepatide.
These are spontaneous reports, not incidence rates or proof that a product caused an event. FDA says underreporting is likely and causality cannot always be determined.
FDA also states that retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition. Their clinical programs belong in the pipeline tracker, not a compounded-product or research-vial comparison.
The separate July 2026 FDA peptide vote results tracker records all fourteen committee votes, including favorable recommendations for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax and recommendations against both Emideltide forms, without confusing committee advice with a final FDA determination. The PT-141 evidence guide separates bremelanotide molecular identity from the exact Vyleesi medicine, Phase 3 outcomes, early male studies, and research-market vials. The Melanotan II evidence guide audits tiny pigmentation and erectile-function studies, reported side effects, serious case reports, and the separately planned FDA meeting before March 2027. The Sermorelin evidence guide resolves Geref's two historical approvals, 2009 withdrawals, pediatric studies, current product differences, and unsupported adult wellness claims. The Thymosin Alpha-1 evidence guide separates mixed human trials, no FDA-approved US product, the 4 to 17 compounding vote, Singapore's exact Zadaxin registration, and research-market listings. The BPC-157 evidence guide separates animal findings, small human records, and the recruiting Phase 2 trial. The TB-500 evidence guide separates the seven-amino-acid fragment from full-length thymosin beta-4 trials. The MOTS-c evidence guide preserves the new Phase 2a registry record beside FDA's conflicting dated evidence search. The DSIP and Emideltide evidence guide separates old intravenous sleep and withdrawal studies from modern subcutaneous claims. The CJC-1295 evidence guide separates DAC from no DAC and preserves the terminated Phase 2 record, while the Selank evidence guide audits small anxiety studies and registry false matches. The KPV evidence guide separates preclinical claims from the missing human administration record. The Epitalon evidence guide separates cell-line telomere findings and melatonin observations from unproven anti-aging, insomnia, dosage, and safety claims.
Read the dated FDA recordQuestions that should not end at a search snippet.
Each answer preserves the category boundary and points back to the primary records below. Nothing here replaces advice from a licensed professional.
Are research peptides safe?
There is no responsible category-wide ‘safe’ answer. A research-use-only listing is not an FDA-approved medicine or a human-use pathway. Its seller name, purity claim, price, review score, or chemical identity record cannot establish clinical safety, sterility, dose, lawful personal use, or that the supplied material matches a represented sample. Peptide Local compares those listings only as non-clinical catalog observations.
Does a peptide COA prove the product is safe?
No. A certificate may report a result for a represented sample, method, date, and lot. It does not automatically establish chain of custody, vial identity, quantity, sterility, endotoxin, contamination, stability, clinical safety, or fitness for a particular use. The useful task is to match the document to the exact lot, identify what was tested, and keep every unmeasured attribute visible.
Are compounded peptides FDA approved?
No. FDA explains that compounded drugs are not FDA approved and do not undergo the agency’s premarket review for safety, effectiveness, or quality. Compounding can have a patient-specific role when an approved drug cannot meet a medical need, but that regulated care route is not interchangeable with an approved brand, an ordinary generic, an investigational candidate, or a research-material seller.
Does a clinical trial listing mean a peptide is available?
No. A ClinicalTrials.gov record describes a research study, including its sponsor, intervention, eligibility criteria, sites, phase, outcomes, and status. Investigational access occurs through an authorized study or another regulated pathway such as FDA expanded access when applicable. A study record, sponsor announcement, or development name does not create an approved product or legitimize a similarly named online vial.
Emergency, exposure, report, or verification?
For collapse, seizure, trouble breathing, or inability to awaken. Use the local emergency number outside the US.
Free, confidential US help is available online or by phone at 1-800-222-1222, 24 hours a day.
Get official help ↗FDA accepts reports about serious reactions, product-quality problems, therapeutic failure, and product-use errors. MedWatch is not emergency care.
Open MedWatch ↗For non-urgent research, check the exact product category, regulator, seller, lot evidence, source date, and stated limits.
Open the verification guide →